Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer
- PMID: 23856908
- DOI: 10.1177/1535370213488483
Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer
Abstract
The opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis is a biological pathway that is present in human ovarian cancer cells and tissues. OGF, chemically termed [Met(5)]-enkephalin, is an endogenous opioid peptide that interfaces with OGFr to delay cells moving through the cell cycle by upregulation of cyclin-dependent inhibitory kinase pathways. OGF inhibitory activity is dose dependent, receptor mediated, reversible, protein and RNA dependent, but not related to apoptosis or necrosis. The OGF-OGFr axis can be targeted for treatment of human ovarian cancer by (i) administration of exogenous OGF, (ii) genetic manipulation to over-express OGFr and (iii) use of low dosages of naltrexone, an opioid antagonist, which stimulates production of OGF and OGFr for subsequent interaction following blockade of the receptor. The OGF-OGFr axis may be a feasible target for treatment of cancer of the ovary (i) in a prophylactic fashion, (ii) following cytoreduction or (iii) in conjunction with standard chemotherapy for additive effectiveness. In summary, preclinical data support the transition of these novel therapies for treatment of human ovarian cancer from the bench to bedside to provide additional targets for treatment of this devastating disease.
Keywords: DNA synthesis; OGF; OGFr; [Met5]-enkephalin; cell proliferation; naltrexone; ovarian cancer.
Similar articles
-
The opioid growth factor-opioid growth factor receptor axis: homeostatic regulator of cell proliferation and its implications for health and disease.Biochem Pharmacol. 2012 Sep 15;84(6):746-55. doi: 10.1016/j.bcp.2012.05.018. Epub 2012 Jun 1. Biochem Pharmacol. 2012. PMID: 22687282
-
Opioid growth factor - opioid growth factor receptor axis inhibits proliferation of triple negative breast cancer.Exp Biol Med (Maywood). 2013 Jun;238(6):589-99. doi: 10.1177/1535370213489492. Exp Biol Med (Maywood). 2013. PMID: 23918871
-
The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice.Gynecol Oncol. 2011 Aug;122(2):382-8. doi: 10.1016/j.ygyno.2011.04.009. Epub 2011 Apr 30. Gynecol Oncol. 2011. PMID: 21531450
-
Diabetic keratopathy and treatment by modulation of the opioid growth factor (OGF)-OGF receptor (OGFr) axis with naltrexone: a review.Brain Res Bull. 2010 Feb 15;81(2-3):236-47. doi: 10.1016/j.brainresbull.2009.08.008. Epub 2009 Aug 14. Brain Res Bull. 2010. PMID: 19683562 Free PMC article. Review.
-
Interaction of opioid growth factor (OGF) and opioid antagonist and their significance in cancer therapy.Int Immunopharmacol. 2019 Oct;75:105785. doi: 10.1016/j.intimp.2019.105785. Epub 2019 Aug 9. Int Immunopharmacol. 2019. PMID: 31404891 Review.
Cited by
-
Low-dose naltrexone extends healthspan and lifespan in C. elegans via SKN-1 activation.iScience. 2024 May 8;27(6):109949. doi: 10.1016/j.isci.2024.109949. eCollection 2024 Jun 21. iScience. 2024. PMID: 38799567 Free PMC article.
-
Involvement of the Opioid Peptide Family in Cancer Progression.Biomedicines. 2023 Jul 14;11(7):1993. doi: 10.3390/biomedicines11071993. Biomedicines. 2023. PMID: 37509632 Free PMC article. Review.
-
CD36+ Fibroblasts Secrete Protein Ligands That Growth-Suppress Triple-Negative Breast Cancer Cells While Elevating Adipogenic Markers for a Model of Cancer-Associated Fibroblast.Int J Mol Sci. 2022 Oct 22;23(21):12744. doi: 10.3390/ijms232112744. Int J Mol Sci. 2022. PMID: 36361532 Free PMC article.
-
Immunomodulatory Role of Neuropeptides in the Cornea.Biomedicines. 2022 Aug 16;10(8):1985. doi: 10.3390/biomedicines10081985. Biomedicines. 2022. PMID: 36009532 Free PMC article. Review.
-
Activation of Oncogenic and Immune-Response Pathways Is Linked to Disease-Specific Survival in Merkel Cell Carcinoma.Cancers (Basel). 2022 Jul 23;14(15):3591. doi: 10.3390/cancers14153591. Cancers (Basel). 2022. PMID: 35892849 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous